{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:24:56Z","timestamp":1788931496578,"version":"build-2803163510"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41588-026-02725-5","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:21Z","timestamp":1788253341000},"page":"2254-2269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states"],"prefix":"10.1038","volume":"58","author":[{"given":"Mor","family":"Zada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kurilovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Sharet-Eshed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Kfir-Erenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Schlossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Zorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Asherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamutal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Chalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-6002","authenticated-orcid":false,"given":"Rotem","family":"Shalita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8059-2656","authenticated-orcid":false,"given":"Maya","family":"Ben Yehuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Zwicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1324-5694","authenticated-orcid":false,"given":"Michelle","family":"von Locquenghien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-9753","authenticated-orcid":false,"given":"Florian","family":"Ingelfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kfir","family":"Mazuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-2364","authenticated-orcid":false,"given":"Eyal","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-1306","authenticated-orcid":false,"given":"Anna","family":"Gurevich-Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-064X","authenticated-orcid":false,"given":"Iuliana","family":"Vaxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-9668","authenticated-orcid":false,"given":"Assaf","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9061-7287","authenticated-orcid":false,"given":"Yael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-877X","authenticated-orcid":false,"given":"Ido","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2725_CR1","doi-asserted-by":"publisher","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 https:\/\/doi.org\/10.1056\/NEJMra1011442 (2011).","DOI":"10.1056\/NEJMra1011442"},{"key":"2725_CR2","doi-asserted-by":"publisher","unstructured":"Kyle, R. A. & Rajkumar, S. V. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 9, 278\u2013288 https:\/\/doi.org\/10.3816\/CLM.2009.n.056 (2009).","DOI":"10.3816\/CLM.2009.n.056"},{"key":"2725_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31, 2443\u20132448 (2017).","journal-title":"Leukemia"},{"key":"2725_CR4","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir, S. et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 103, e412\u2013e415 (2018).","journal-title":"Haematologica"},{"key":"2725_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos, M. A., Richardson, P. G., Moreau, P. & Anderson, K. C. Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12, 42\u201354 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2725_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2725_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMc2211969","volume":"387","author":"CA Crowther","year":"2022","unstructured":"Crowther, C. A. & Tran, T. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 1721\u20131723 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2725_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","volume":"3","author":"Y Yan","year":"2019","unstructured":"Yan, Y. et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 3, 2895\u20132904 (2019).","journal-title":"Blood Adv."},{"key":"2725_CR10","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.3390\/cancers14174082","volume":"14","author":"D Dima","year":"2022","unstructured":"Dima, D. et al. Multiple myeloma therapy: emerging trends and challenges. Cancers 14, 4082 (2022).","journal-title":"Cancers"},{"key":"2725_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo, W. H. et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 134, 30\u201343 (2019).","journal-title":"Blood"},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold, N. et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood 128, 1735\u20131744 (2016).","journal-title":"Blood"},{"key":"2725_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz, M. et al. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 14, 214 (2024).","journal-title":"Blood Cancer J."},{"key":"2725_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","volume":"82","author":"B Paul","year":"2022","unstructured":"Paul, B., Rodriguez, C. & Usmani, S. Z. BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy. Drugs 82, 613 (2022).","journal-title":"Drugs"},{"key":"2725_CR16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2725_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-133873","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari, A. et al. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) \u00d7 CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM). Blood 136, 40\u201341 (2020).","journal-title":"Blood"},{"key":"2725_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.24131","volume":"90","author":"N Majithia","year":"2015","unstructured":"Majithia, N. et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am. J. Hematol. 90, 981\u2013985 (2015).","journal-title":"Am. J. Hematol."},{"key":"2725_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32, 986\u2013995 (2018).","journal-title":"Leukemia"},{"key":"2725_CR20","doi-asserted-by":"publisher","unstructured":"van de Donk, N. W. C. J. et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat. Rev. 37, 266\u2013283 https:\/\/doi.org\/10.1016\/j.ctrv.2010.08.008 (2011).","DOI":"10.1016\/j.ctrv.2010.08.008"},{"key":"2725_CR21","doi-asserted-by":"publisher","unstructured":"van De Donk, N. W. C. J. & Usmani, S. Z. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 https:\/\/doi.org\/10.3389\/fimmu.2018.02134 (2018).","DOI":"10.3389\/fimmu.2018.02134"},{"key":"2725_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo.2016.3516","volume":"49","author":"SR Krishnan","year":"2016","unstructured":"Krishnan, S. R., Jaiswal, R., Brown, R. D., Luk, F. & Bebawy, M. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int. J. Oncol. 49, 33\u201350 (2016).","journal-title":"Int. J. Oncol."},{"key":"2725_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth, D. et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist. Updates 18, 18\u201335 (2015).","journal-title":"Drug Resist. Updates"},{"key":"2725_CR24","doi-asserted-by":"publisher","unstructured":"Harding, T., Baughn, L., Kumar, S. & Van Ness, B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 33, 863\u2013883 https:\/\/doi.org\/10.1038\/s41375-018-0362-z (2019).","DOI":"10.1038\/s41375-018-0362-z"},{"key":"2725_CR25","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia, N. et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 30, 2208\u20132213 (2016).","journal-title":"Leukemia"},{"key":"2725_CR26","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper, R. et al. A gene expression signature for high-risk multiple myeloma. Leukemia 26, 2406\u20132413 (2012).","journal-title":"Leukemia"},{"key":"2725_CR27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy, J. D. et al. Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"2725_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/ijc.20491","volume":"112","author":"R Garc\u00eda-Sanz","year":"2004","unstructured":"Garc\u00eda-Sanz, R. et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int. J. Cancer 112, 884\u2013889 (2004).","journal-title":"Int. J. Cancer"},{"key":"2725_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2010","unstructured":"Hose, D. et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96, 87 (2010).","journal-title":"Haematologica"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajh.20125","volume":"77","author":"S Kumar","year":"2004","unstructured":"Kumar, S., Rajkumar, S. V., Greipp, P. R. & Witzig, T. E. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am. J. Hematol. 77, 7\u201311 (2004).","journal-title":"Am. J. Hematol."},{"key":"2725_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-025-01232-w","volume":"15","author":"S Zanwar","year":"2025","unstructured":"Zanwar, S. et al. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 15, 1\u20136 (2025).","journal-title":"Blood Cancer J."},{"key":"2725_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0165-4608(99)00009-6","volume":"113","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar, S. V. et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet. Cytogenet. 113, 73\u201377 (1999).","journal-title":"Cancer Genet. Cytogenet."},{"key":"2725_CR33","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"2725_CR34","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget, S. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat. Genet. 56, 1878\u20131889 (2024).","journal-title":"Nat. Genet."},{"key":"2725_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/leu.2015.341","volume":"30","author":"WJ Chng","year":"2016","unstructured":"Chng, W. J. et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 30, 1071\u20131078 (2016).","journal-title":"Leukemia"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","volume":"96","author":"J Moreaux","year":"2011","unstructured":"Moreaux, J. et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96, 574\u2013582 (2011).","journal-title":"Haematologica"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/cancers17040653","volume":"17","author":"S Li","year":"2025","unstructured":"Li, S. et al. Multiple myeloma insights from single-cell analysis: clonal evolution, the microenvironment, therapy evasion, and clinical implications. Cancers 17, 653 (2025).","journal-title":"Cancers"},{"key":"2725_CR38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.2023021523","volume":"142","author":"MK Samur","year":"2023","unstructured":"Samur, M. K., Szalat, R. & Munshi, N. C. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood 142, 313\u2013324 (2023).","journal-title":"Blood"},{"key":"2725_CR39","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","volume":"114","author":"M Jourdan","year":"2009","unstructured":"Jourdan, M. et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114, 5173 (2009).","journal-title":"Blood"},{"key":"2725_CR40","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","journal-title":"Nat. Med."},{"key":"2725_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta, A. K. et al. Single-cell profiling of tumour evolution in multiple myeloma \u2014 opportunities for precision medicine. Nat. Rev. Clin. Oncol. 19, 223\u2013236 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2725_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/BS9.0000000000000172","volume":"5","author":"J Du","year":"2023","unstructured":"Du, J., Gu, X. R., Yu, X. X., Cao, Y. J. & Hou, J. Essential procedures of single-cell RNA sequencing in multiple myeloma and its translational value. Blood Sci. 5, 221\u2013236 (2023).","journal-title":"Blood Sci."},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier, S. M. et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat. Commun. 12, 1\u201316 (2021).","journal-title":"Nat. Commun."},{"key":"2725_CR46","first-page":"1","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nature Commun. 12, 1\u201318 (2021).","journal-title":"Nature Commun."},{"key":"2725_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33944-z","volume":"13","author":"R Boiarsky","year":"2022","unstructured":"Boiarsky, R. et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat. Commun. 13, 1\u201315 (2022).","journal-title":"Nat. Commun."},{"key":"2725_CR48","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023019758","volume":"142","author":"AM Poos","year":"2023","unstructured":"Poos, A. M. et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood 142, 1633\u20131646 (2023).","journal-title":"Blood"},{"key":"2725_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers12010012","volume":"12","author":"S Ozaki","year":"2019","unstructured":"Ozaki, S. et al. Polyclonal immunoglobulin recovery after autologous stem cell transplantation is an independent prognostic factor for survival outcome in patients with multiple myeloma. Cancers 12, 12 (2019).","journal-title":"Cancers"},{"key":"2725_CR50","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1016\/j.bbmt.2019.12.485","volume":"26","author":"KC Miller","year":"2020","unstructured":"Miller, K. C. et al. The impact of proliferating polyclonal plasma cells on outcome after autologous stem cell transplantation in multiple myeloma. Biol. Blood Marrow Transplant. 26, S239 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2725_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cyto.b.22068","volume":"102","author":"N Das","year":"2022","unstructured":"Das, N. et al. Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma. Cytometry B Clin. Cytom. 102, 209\u2013219 (2022).","journal-title":"Cytometry B Clin. Cytom."},{"key":"2725_CR52","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","volume":"105","author":"KA Frerichs","year":"2020","unstructured":"Frerichs, K. A. et al. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica 105, e302\u2013e306 (2020).","journal-title":"Haematologica"},{"key":"2725_CR53","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.1247651","volume":"343","author":"DA Jaitin","year":"2014","unstructured":"Jaitin, D. A. et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343, 776\u2013779 (2014).","journal-title":"Science"},{"key":"2725_CR54","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41596-019-0164-4","volume":"14","author":"H Keren-Shaul","year":"2019","unstructured":"Keren-Shaul, H. et al. MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing. Nat. Protoc. 14, 1841\u20131862 (2019).","journal-title":"Nat. Protoc."},{"key":"2725_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1812-2","volume":"20","author":"Y Baran","year":"2019","unstructured":"Baran, Y. et al. MetaCell: analysis of single-cell RNA-seq data using K-nn graph partitions. Genome Biol. 20, 206 (2019).","journal-title":"Genome Biol."},{"key":"2725_CR56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41587-021-01206-w","volume":"40","author":"A Gayoso","year":"2022","unstructured":"Gayoso, A. et al. A Python library for probabilistic analysis of single-cell omics data. Nat. Biotechnol. 40, 163\u2013166 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2725_CR57","unstructured":"Tickle, T., Tirosh, I., Georgescu, C., Brown, M. & Haas, B. inferCNV of the Trinity CTAT Project. Version 1.18.1. GitHub https:\/\/github.com\/broadinstitute\/inferCNV (2019)."},{"key":"2725_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97, 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"2725_CR59","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","volume":"102","author":"K Tarte","year":"2003","unstructured":"Tarte, K., Zhan, F., De Vos, J., Klein, B. & Shaughnessy, J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102, 592\u2013600 (2003).","journal-title":"Blood"},{"key":"2725_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imm.13344","volume":"164","author":"A Grasseau","year":"2021","unstructured":"Grasseau, A. et al. The diversity of the plasmablast signature across species and experimental conditions: a meta-analysis. Immunology 164, 120 (2021).","journal-title":"Immunology"},{"key":"2725_CR61","doi-asserted-by":"publisher","first-page":"112682","DOI":"10.1016\/j.celrep.2023.112682","volume":"42","author":"M Duan","year":"2023","unstructured":"Duan, M. et al. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep. 42, 112682 (2023).","journal-title":"Cell Rep."},{"key":"2725_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"2725_CR63","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41408-021-00554-9","volume":"11","author":"S Talluri","year":"2021","unstructured":"Talluri, S. et al. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 11, 166 (2021).","journal-title":"Blood Cancer J."},{"key":"2725_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07027-4","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets. Cell Death Dis. 15, 672 (2024).","journal-title":"Cell Death Dis."},{"key":"2725_CR65","doi-asserted-by":"publisher","first-page":"1458638","DOI":"10.3389\/fimmu.2024.1458638","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X. et al. Unveiling the cellular landscape: insights from single-cell RNA sequencing in multiple myeloma. Front. Immunol. 15, 1458638 (2024).","journal-title":"Front. Immunol."},{"key":"2725_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0169-8","volume":"7","author":"V Greiff","year":"2015","unstructured":"Greiff, V. et al. A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status. Genome Med. 7, 49 (2015).","journal-title":"Genome Med."},{"key":"2725_CR67","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nri1572","volume":"5","author":"M Shapiro-Shelef","year":"2005","unstructured":"Shapiro-Shelef, M. & Calame, K. C. Regulation of plasma-cell development. Nat. Rev. Immunol. 5, 230\u2013242 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2725_CR68","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1084\/jem.20040973","volume":"200","author":"A Kallies","year":"2004","unstructured":"Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J. Exp. Med. 200, 967\u2013977 (2004).","journal-title":"J. Exp. Med."},{"key":"2725_CR69","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160\u2013171 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2725_CR70","doi-asserted-by":"publisher","first-page":"eabl5197","DOI":"10.1126\/science.abl5197","volume":"376","author":"C Dom\u00ednguez Conde","year":"2022","unstructured":"Dom\u00ednguez Conde, C. et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science 376, eabl5197 (2022).","journal-title":"Science"},{"key":"2725_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinf. 11, 1\u20139 (2010.","journal-title":"BMC Bioinf."},{"key":"2725_CR72","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/25141","volume":"396","author":"F Li","year":"1998","unstructured":"Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580\u2013584 (1998).","journal-title":"Nature"},{"key":"2725_CR73","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1101\/gr.192237.115","volume":"25","author":"MS Kowalczyk","year":"2015","unstructured":"Kowalczyk, M. S. et al. Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. Genome Res. 25, 1860\u20131872 (2015).","journal-title":"Genome Res."},{"key":"2725_CR74","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cellsig.2010.11.006","volume":"23","author":"J Iyer","year":"2011","unstructured":"Iyer, J., Moghe, S., Furukawa, M. & Tsai, M. Y. What\u2019s Nu(SAP) in mitosis and cancer? Cell. Signal. 23, 991\u2013998 (2011).","journal-title":"Cell. Signal."},{"key":"2725_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0633-8","volume":"32","author":"TL He","year":"2015","unstructured":"He, T. L. et al. The c-Myc\u2013LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med. Oncol. 32, 187 (2015).","journal-title":"Med. Oncol."},{"key":"2725_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fcell.2014.00005","volume":"2","author":"N Ozturk","year":"2014","unstructured":"Ozturk, N., Singh, I., Mehta, A., Braun, T. & Barreto, G. HMGA proteins as modulators of chromatin structure during transcriptional activation. Front. Cell Dev. Biol. 2, 5 (2014).","journal-title":"Front. Cell Dev. Biol."},{"key":"2725_CR77","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.molcel.2018.03.030","volume":"70","author":"A Zirkel","year":"2018","unstructured":"Zirkel, A. et al. HMGB2 loss upon senescence entry disrupts genomic organization and induces CTCF clustering across cell types. Mol. Cell 70, 730\u2013744.e6 (2018).","journal-title":"Mol. Cell"},{"key":"2725_CR78","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/147323001003800501","volume":"38","author":"J Lee","year":"2010","unstructured":"Lee, J. & Kim, S. S. An overview of cyclophilins in human cancers. J. Int. Med. Res. 38, 1561\u20131574 (2010).","journal-title":"J. Int. Med. Res."},{"key":"2725_CR79","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature07851","volume":"458","author":"DA Pomeranz Krummel","year":"2009","unstructured":"Pomeranz Krummel, D. A., Oubridge, C., Leung, A. K. W., Li, J. & Nagai, K. Crystal structure of human spliceosomal U1 snRNP at 5.5 resolution. Nature 458, 475\u2013480 (2009).","journal-title":"Nature"},{"key":"2725_CR80","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.it.2022.01.003","volume":"43","author":"D Morgan","year":"2022","unstructured":"Morgan, D. & Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 43, 210\u2013229 (2022).","journal-title":"Trends Immunol."},{"key":"2725_CR81","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal, S. et al. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am. J. Cancer Res. 12, 2950\u20132965 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"2725_CR82","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/bjh.20046","volume":"206","author":"L Cani","year":"2025","unstructured":"Cani, L., Gupta, V. A. & Kaufman, J. L. BCL2 inhibition for multiple myeloma and AL amyloidosis. Br. J. Haematol. 206, 1285\u20131296 (2025).","journal-title":"Br. J. Haematol."},{"key":"2725_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini, G. F., Ribeiro, G. N., Pinto Neto, J. V., Campos, L. T. & Hamerschlak, N. BCL-2 as therapeutic target for hematological malignancies. J. Hematol. Oncol. 11, 1\u201315 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2725_CR84","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood-2019-126094","volume":"134","author":"S Harrison","year":"2019","unstructured":"Harrison, S. et al. T(11;14) and high BCL2 Expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood 134, 142 (2019).","journal-title":"Blood"},{"key":"2725_CR85","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","volume":"21","author":"C Hetz","year":"2020","unstructured":"Hetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421\u2013438 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2725_CR86","doi-asserted-by":"publisher","first-page":"691705","DOI":"10.3389\/fonc.2021.691705","volume":"11","author":"L Meng","year":"2021","unstructured":"Meng, L. et al. S100A9 derived from myeloma associated myeloid cells promotes TNFSF13B\/TNFRSF13B-dependent proliferation and survival of myeloma cells. Front. Oncol. 11, 691705 (2021).","journal-title":"Front. Oncol."},{"key":"2725_CR87","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"2725_CR88","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1947601913486348","volume":"4","author":"V Gandin","year":"2013","unstructured":"Gandin, V., Senft, D., Topisirovic, I. & Ronai, Z. A. RACK1 function in cell motility and protein synthesis. Genes Cancer 4, 369 (2013).","journal-title":"Genes Cancer"},{"key":"2725_CR89","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong, N. et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 141, 1574\u20131583 (2023).","journal-title":"Blood"},{"key":"2725_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary, G. S. et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 6, e1593 (2015).","journal-title":"Cell Death Dis."},{"key":"2725_CR91","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.V124.21.2001.2001","volume":"124","author":"I Misiewicz-Krzeminska","year":"2014","unstructured":"Misiewicz-Krzeminska, I. et al. Post-transcriptional modifications explain the overexpression of CCND2 in multiple myeloma. Blood 124, 2001 (2014).","journal-title":"Blood"},{"key":"2725_CR92","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1007\/s00277-024-06026-x","volume":"103","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. T(11;14) with multiple myeloma: standard risk survival but slow and poor response. Ann. Hematol. 103, 5573\u20135581 (2024).","journal-title":"Ann. Hematol."},{"key":"2725_CR93","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel, H., Kocemba, K. A., Spaargaren, M. & Pals, S. T. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia 33, 1063 (2019).","journal-title":"Leukemia"},{"key":"2725_CR94","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","volume":"117","author":"P Neri","year":"2011","unstructured":"Neri, P. et al. Integrin \u03b27-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 117, 6202 (2011).","journal-title":"Blood"},{"key":"2725_CR95","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.molcel.2011.08.042","volume":"44","author":"AJ Kuo","year":"2011","unstructured":"Kuo, A. J. et al. NSD2 Links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609\u2013620 (2011).","journal-title":"Mol. Cell"},{"key":"2725_CR96","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724 (2006).","journal-title":"Blood"},{"key":"2725_CR97","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","volume":"95","author":"N Zojer","year":"2000","unstructured":"Zojer, N. et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95, 1925\u20131930 (2000).","journal-title":"Blood"},{"key":"2725_CR98","doi-asserted-by":"publisher","first-page":"e2024062","DOI":"10.4084\/MJHID.2024.062","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa, U., Pelosi, E., Castelli, G. & Leone, G. Recent advances in the definition of the molecular alterations occurring in multiple myeloma. Mediterr. J. Hematol. Infect. Dis. 16, e2024062 (2024).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"2725_CR99","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"2725_CR100","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41420-025-02551-4","volume":"11","author":"AB Ventura","year":"2025","unstructured":"Ventura, A. B. et al. MAFB: a key regulator of myeloid commitment involved in hematological diseases. Cell Death Discov. 11, 276 (2025).","journal-title":"Cell Death Discov."},{"key":"2725_CR101","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"CJ Neuse","year":"2020","unstructured":"Neuse, C. J. et al. Genome instability in multiple myeloma. Leukemia 34, 2887\u20132897 (2020).","journal-title":"Leukemia"},{"key":"2725_CR102","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/ni944","volume":"4","author":"N Watanabe","year":"2003","unstructured":"Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670\u2013679 (2003).","journal-title":"Nat. Immunol."},{"key":"2725_CR103","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91 (2014).","journal-title":"Cancer Cell"},{"key":"2725_CR104","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"2725_CR105","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"2725_CR106","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","volume":"64","author":"R Fonseca","year":"2004","unstructured":"Fonseca, R. et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 64, 1546\u20131558 (2004).","journal-title":"Cancer Res."},{"key":"2725_CR107","doi-asserted-by":"publisher","unstructured":"Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335\u2013348 https:\/\/doi.org\/10.1038\/nrc3257 (2012).","DOI":"10.1038\/nrc3257"},{"key":"2725_CR108","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1073\/pnas.171308498","volume":"98","author":"RS Davis","year":"2001","unstructured":"Davis, R. S., Wang, Y. H., Kubagawa, H. & Cooper, M. D. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc. Natl Acad. Sci. USA 98, 9772\u20139777 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2725_CR109","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1146\/annurev.immunol.25.022106.141541","volume":"25","author":"RS Davis","year":"2007","unstructured":"Davis, R. S. Fc receptor-like molecules. Annu. Rev. Immunol. 25, 525\u2013560 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"2725_CR110","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.4049\/jimmunol.1002305","volume":"185","author":"TA Jackson","year":"2010","unstructured":"Jackson, T. A., Haga, C. L., Ehrhardt, G. R. A., Davis, R. S. & Cooper, M. D. FcR-like 2 inhibition of B cell receptor-mediated activation of B cells. J. Immunol. 185, 7405\u20137412 (2010).","journal-title":"J. Immunol."},{"key":"2725_CR111","first-page":"29","volume":"382","author":"FJ Li","year":"2014","unstructured":"Li, F. J. et al. Emerging roles for the FCRL family members in lymphocyte biology and disease. Curr. Top. Microbiol. Immunol. 382, 29\u201350 (2014).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2725_CR112","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"114","author":"BA Walker","year":"2010","unstructured":"Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 114, e56 (2010).","journal-title":"Blood"},{"key":"2725_CR113","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/leu.2013.12","volume":"27","author":"MF Kaiser","year":"2013","unstructured":"Kaiser, M. F. et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27, 1754\u20131757 (2013).","journal-title":"Leukemia"},{"key":"2725_CR114","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"2725_CR115","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva, B. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J. Clin. Oncol. 38, 784\u2013792 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2725_CR116","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"2725_CR117","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","volume":"12","author":"KH Maclachlan","year":"2021","unstructured":"Maclachlan, K. H. et al. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nat. Commun. 12, 5172 (2021).","journal-title":"Nat. Commun."},{"key":"2725_CR118","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"2725_CR119","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911\u20133920 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2725_CR120","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger, E. et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat. Cancer 5, 1267\u20131284 (2024).","journal-title":"Nat. Cancer"},{"key":"2725_CR121","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","volume":"83","author":"L Yao","year":"2023","unstructured":"Yao, L. et al. Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma. Cancer Res. 83, 1214\u20131233 (2023).","journal-title":"Cancer Res."},{"key":"2725_CR122","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1182\/blood-2021-149701","volume":"138","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Single cell RNA sequencing in patients enrolled in a selinexor clinical trial reveals overexpression of alternative nuclear export pathways associated with resistance to selinexor in refractory multiple myeloma. Blood 138, 2725 (2021).","journal-title":"Blood"},{"key":"2725_CR123","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","volume":"28","author":"S Kfir-Erenfeld","year":"2022","unstructured":"Kfir-Erenfeld, S. et al. Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin. Cancer Res. 28, 5156\u20135166 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2725_CR124","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cell.2015.11.013","volume":"163","author":"A Franziska Paul","year":"2015","unstructured":"Franziska Paul, A. et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell 163, 1663\u20131677 (2015).","journal-title":"Cell"},{"key":"2725_CR125","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290 (2017).","journal-title":"Cell"},{"key":"2725_CR126","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1158\/0008-5472.CAN-25-3596","volume":"85","author":"A Gurevich-Shapiro","year":"2025","unstructured":"Gurevich-Shapiro, A. et al. Distinct cellular and molecular patterns in pretreatment peripheral blood are associated with CAR T-cell outcomes in diffuse large B-cell lymphoma. Cancer Res. 85, 5066\u20135083 (2025).","journal-title":"Cancer Res."},{"key":"2725_CR127","doi-asserted-by":"crossref","unstructured":"Zada, M. et al. A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states. Zenodo https:\/\/zenodo.org\/records\/21390066 (2026).","DOI":"10.1038\/s41588-026-02725-5"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02725-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:02:54Z","timestamp":1788890574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02725-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1038\/s41588-026-02725-5","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Z., A.K. and I. Amit have filed a patent application related to this work. Y.C. is a consultant for Roche, Takeda, BMS, Pfizer, JNJ, Medison Pharma, GSK, Amgen, Sanofi and Aventis. I. Amit is a member of the Cell Advisory Board and a consultant for Sanofi. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}